Background: Heart disease diagnosis is a challenging task and it is important to explore useful information from the massive amount of electrocardiogram (ECG) records of patients. The high-precision diagnostic identification of ECG can save clinicians and cardiologists considerable time while helping reduce the possibility of misdiagnosis at the same time.Currently, some deep learning-based methods can effectively perform feature selection and classification prediction, reducing the consumption of manpower. Methods: In this work, an end-to-end deep learning framework based on convolutional neural network (CNN) is proposed for ECG signal processing and arrhythmia classification. In the framework, a transformer network is embedded in CNN to capture the temporal information of ECG signals and a new link constraint is introduced to the loss function to enhance the classification ability of the embedding vector. Results: To evaluate the proposed method, extensive experiments based on real-world data were conducted. Experimental results show that the proposed model achieve better performance than most baselines. The experiment results also proved that the transformer network pays more attention to the temporal continuity of the data and captures the hidden deep features of the data well. The link constraint strengthens the constraint on the embedded features and effectively suppresses the effect of data imbalance on the results. Conclusions: In this paper, an end-to-end model is used to process ECG signal and classify arrhythmia. The model combine CNN and Transformer network to extract temporal information in ECG signal and is capable of performing arrhythmia classification with acceptable accuracy. The model can help cardiologists perform assisted diagnosis of heart disease and improve the efficiency of healthcare delivery.

Dental caries is a prevalent disease of the human oral cavity. Given the lack of research on digital images for caries detection, we construct a caries detection dataset based on the caries images annotated by professional dentists and propose RDFNet, a fast caries detection method for the requirement of detecting caries on portable devices. The method incorporates the transformer mechanism in the backbone network for feature extraction, which improves the accuracy of caries detection and uses the FReLU activation function for activating visual-spatial information to improve the speed of caries detection. The experimental results on the image dataset constructed in this study show that the accuracy and speed of the method for caries detection are improved compared with the existing methods, achieving a good balance in accuracy and speed of caries detection, which can be applied to smart portable devices to facilitate human dental health management.

The prevalence of Parkinson’s disease increases a tremendous medical and economic burden to society. Therefore, the effective drugs are urgently required. However, the traditional development of effective drugs is costly and risky. Drug repurposing, which identifies new applications for existing drugs, is a feasible strategy for discovering new drugs for Parkinson’s disease. Drug repurposing is based on sufficient medical knowledge. The local medical knowledge base with manually labeled data contains a large number of accurate, but not novel, medical knowledge, while the medical literature containing the latest knowledge is difficult to utilize, because of unstructured data. This paper proposes a framework, named Drug Repurposing for Parkinson’s disease by integrating Knowledge Graph Completion method and Knowledge Fusion of medical literature data (DRKF) in order to make full use of a local medical knowledge base containing accurate knowledge and medical literature with novel knowledge. DRKF first extracts the relations that are related to Parkinson’s disease from medical literature and builds a medical literature knowledge graph. After that, the literature knowledge graph is fused with a local medical knowledge base that integrates several specific medical knowledge sources in order to construct a fused medical knowledge graph. Subsequently, knowledge graph completion methods are leveraged to predict the drug candidates for Parkinson’s disease by using the fused knowledge graph. Finally, we employ classic machine learning methods to repurpose the drug for Parkinson’s disease and compare the results with the method only using the literature-based knowledge graph in order to confirm the effectiveness of knowledge fusion. The experiment results demonstrate that our framework can achieve competitive performance, which confirms the effectiveness of our proposed DRKF for drug repurposing against Parkinson’s disease. It could be a supplement to traditional drug discovery methods.

The current global crisis caused by COVID-19 almost halted normal life in most parts of the world. Due to the long development cycle for new drugs, drug repositioning becomes an effective method of screening drugs for COVID-19. To find suitable drugs for COVID-19, we add COVID-19-related information into our medical knowledge graph and utilize a knowledge-graph-based drug repositioning method to screen potential therapeutic drugs for COVID-19. Specific steps are as follows. Firstly, the information about COVID-19 is collected from the latest published literature, and gene targets of COVID-19 are added to the knowledge graph. Then, the information of COVID-19 of the knowledge graph is extracted and a drug–disease interaction prediction model based on Graph Convolutional Network with Attention (Att-GCN) is established. Att-GCN is used to extract features from the knowledge graph and the prediction matrix reconstructed through matrix operation. We evaluate the model by predicting drugs for both ordinary diseases and COVID-19. The model can achieve area under curve (AUC) of 0.954 and area under the precise recall area curve (AUPR) of 0.851 for ordinary diseases. On the drug repositioning experiment for COVID-19, five drugs predicted by the models have proved effective in clinical treatment. The experimental results confirm that the model can predict drug–disease interaction effectively for both normal diseases and COVID-19.